Spartan 3 (Mod GRF 1-29 / GHRP-6) Blend
Also known as: Spartan 3, Mod GRF 1-29 + GHRP-6
A growth-hormone-secretagogue blend combining Modified GRF 1-29 (a CJC-1295 without DAC GHRH analog) with GHRP-6 to stimulate pulsatile growth hormone release. It is studied for recovery, body composition, and appetite.
Last updated
Mechanism of Action
Modified GRF 1-29 is a stabilized growth-hormone-releasing hormone analog that binds the GHRH receptor on pituitary somatotrophs, increasing the amplitude of growth hormone pulses via cAMP/PKA signaling. GHRP-6 is a growth-hormone-releasing peptide that activates the ghrelin/GHS-R1a receptor, triggering a separate intracellular pathway that amplifies GH release and suppresses somatostatin tone, while also stimulating appetite. Used together, the GHRH analog and the GHS act synergistically through their distinct receptors to produce a larger, more physiologic GH pulse than either alone, which in turn raises IGF-1.
- Half-life
- Short for both components; Modified GRF 1-29 is roughly 30 minutes and GHRP-6 is on the order of 15-60 minutes, producing a brief GH pulse.
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Stimulates pulsatile growth hormone secretion
- May raise IGF-1 to support recovery and lean mass
- Synergistic GHRH-plus-GHS mechanism for larger GH pulses
- Studied for improved sleep quality and tissue repair
- GHRP-6 component stimulates appetite
- Explored for body-composition and anti-aging research
Potential Side Effects
- Water retention and tingling or numbness in extremities
- Increased hunger from GHRP-6
- Injection-site irritation
- Transient rise in blood glucose or insulin resistance
- Flushing, lightheadedness, or fatigue
Common Dosing
For research use only and not medical advice; literature describes Modified GRF 1-29 and GHRP-6 each around 100 mcg per dose, often combined and administered one to three times daily before sleep or fasted. The blend has no standardized human protocol.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or suspected malignancy
- Pregnancy and breastfeeding
- Uncontrolled diabetes or significant insulin resistance
CJC-1295 (No DAC) / GHRP-6 Blend
This blend combines CJC-1295 without DAC (Mod GRF 1-29), a GHRH analog, with GHRP-6, a ghrelin-mimetic secretagogue noted for strong appetite stimulation, to synergistically boost growth hormone release. Both are unapproved research peptides.
Ipamorelin
A selective ghrelin receptor agonist (growth hormone secretagogue) prized for stimulating GH release with minimal effect on cortisol or prolactin. Considered one of the gentler GH peptides.
Sermorelin
A GHRH analog comprising the first 29 amino acids of growth hormone releasing hormone, historically used to assess and stimulate pituitary GH output. A gentler, physiologic GH peptide.
Tesamorelin
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
GHRH (1-29)
GHRH (1-29) is the biologically active N-terminal fragment of human growth hormone-releasing hormone, used in research to stimulate the pituitary to release growth hormone. The synthetic analog of this fragment is also known as sermorelin.
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006
- View
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
2005
- View
Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity
1993
- View
Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level
1995